Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary

Tarsus Pharmaceuticals

06/08/2026 16:40

Tarsus Pharmaceuticals, Inc. TARS.OQ reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -48 cents.  The mean expectation of nine analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -32 cents to -7 cents per share.
Revenue rose 69.4% to $173.91 million from a year ago; analysts expected $169.68 million. 
Tarsus Pharmaceuticals, Inc.'s reported EPS for the quarter was a loss of 43 cents​.
The company reported a quarterly loss of $18.55 million.
Tarsus Pharmaceuticals, Inc. shares had fallen by 2.6% this quarter and lost 25.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.9% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for Tarsus Pharmaceuticals, Inc. is $89.00, about 31.1% above its last closing price of $61.29
This summary was machine generated from LSEG data August 6 at 03:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.20
-0.49
Missed
Mar. 31 2026 
-0.37
-0.16
Beat
Dec. 31 2025 
-0.10
-0.20
Missed
Sep. 30 2025 
-0.35
-0.30
Beat